Am J Transplant, Volume 19, Suppl 3 Archives - Page 121 of 214 - ATC Abstracts

2019 American Transplant Congress
Prolongation of Allograft Survival via Donor MHC Chimerism Induced by Exosomes
B. Gonzalez Nolasco¹, M. Wang¹, W. Orent¹, A. Prunevieille¹, J. O¹, K. Ahrens¹, J. C. Madsen², G. Benichou¹
¹Department of Surgery, Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, ²Department of Surgery, Center for Transplantation Sciences, Division of Cardiac Surgery, Massachusetts General Hospital, Boston, MA
*Purpose: Achieving robust and durable host immune tolerance of allogeneic transplants is the ultimate goal in clinical transplantation. Mixed chimerism induced via donor bone marrow…
2019 American Transplant Congress
Progress Using Genetically Engineered Pigs for Lung Xenotransplantation
L. Burdorf¹, C. Laird², S. Sendil², T. Zhang², D. Parsell², I. Tatarov², B. Cerel¹, Z. Abady¹, S. Pratts¹, C. J. Phelps³, D. L. Ayares³, A. M. Azimzadeh¹, R. N. Pierson III¹
¹Surgery, Center for Transplantation Sciences, Massachusetts General Hospital, Charlestown, MA, ²Surgery, University of MD, Baltimore, MD, ³Revivicor, Blacksburg, VA
*Purpose: CRISPR/Cas9 gene editing techniques facilitate generation of pigs with multiple genetic modifications. We report results associated with multiple mechanistically targeted gene knock-outs and transgenes,…
2019 American Transplant Congress
OPO Aggressiveness Index: A Novel OPO Performance Metric That Incentivizes Pursuit of Marginal Deceased Donor Candidates
L. Liyanage, Y. Yu, K. Jackson, J. Garonzik-Wang, D. Segev, A. Massie
Johns Hopkins, Baltimore, MD
*Purpose: Of 2.5M deaths in the US every year, only 10,000 are recovered for transplantation; recovery of organs from older donors is rare although similar…
2019 American Transplant Congress
Geographic Disparities in Heart Transplant Rates
M. Kosztowski, S. Yu, A. Kilic, A. Massie, S. Zhou, D. Segev, S. Gentry
JHU, Baltimore, MD
*Purpose: One of the motivations for the recent changes to the heart allocation policy was to reduce geographic disparities. We investigated whether heart transplant (HT)…
2019 American Transplant Congress
Clazakizumab (CLZ, Anti-IL-6 Antibody) and Tocilizumab (TCZ, Anti-IL-6 Receptor [r] Antibody) Treatments Differentially Affect IL-6/IL-6R Signaling by Modulating Soluble IL-6R (sIL-6R) and gp130 (sgp130) in Kidney Transplant Patients (KTx Pts) Treated for Chronic Antibody-Mediated Rejection (cABMR)
B. Shin, S. Ge, A. Petrosyan, N. F. Ammerman, A. A. Vo, S. C. Jordan, M. Toyoda
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: We have reported successful use of TCZ for cABMR treatment in HLA-sensitized KTx Pts. CLZ is 3-120 times more potent than TCZ in IL-6/IL-6R…
2019 American Transplant Congress
Risk Stratification of Cytomegalovirus Seropositive Kidney Transplant Recipients for CMV Infection
M. M. Azar¹, A. Baghban¹, K. Belfield¹, R. Assi², M. Malinis¹
¹Yale University, New Haven, CT, ²University of Pennsylvania, Philadelphia, PA
*Purpose: Current consensus guidelines for CMV prevention recommend valganciclovir (VGCV) prophylaxis for 3 months after transplantation for CMV R+ kidney transplant recipients (KTR). This standard…
2019 American Transplant Congress
Successful Use of Hizentra to Address BK Viremia in Pediatric Transplant Population
K. Gruenkemeyer, E. Wood, A. Beck, C. Belsha
Pediatric Nephrology, Saint Louis University, Saint Louis, MO
*Purpose: BK viremia is an important problem in the pediatric renal transplant population leading to increased risk for viral associated nephropathy in the transplant. Early…
2019 American Transplant Congress
Islet Xenotransplantation: A Quest for Clinically Available Immunosuppression Regimens
Z. W. Fitch¹, Q. Gao¹, R. P. Davis¹, M. S. Mulvihill¹, M. Song¹, F. Leopardi¹, M. Ribeiro¹, T. How¹, K. Reimann², G. R. Devi¹, B. H. Collins¹, A. D. Kirk¹
¹Surgery, Duke University, Durham, NC, ²University of Massachusetts, Worcester, MA
*Purpose: Porcine islet xenotransplantation has progressed significantly in non-human primate (NHP) studies. However, all successful NHP studies have relied upon immunosuppressive regimens that utilize drugs…
2019 American Transplant Congress
Discard Patterns in Donors with Non Alcoholic Fatty Liver Disease
M. MacConmara¹, A. Mufti², S. Hanish¹, P. Vagefi¹, S. Tujius², C. Hwang¹
¹Surgery (Division of Surgical Transplantation), UT Southwestern Medical Center, Dallas, TX, ²Medicine (Transplant Hepatology), UT Southwestern Medical Center, Dallas, TX
*Purpose: Obesity and nonalcoholic fatty liver disease (NAFLD) are major health issues affecting 20-50% of the US adult population and are increasingly prevalent in potential…
2019 American Transplant Congress
Association of Tacrolimus-Level Variance with De Novo DSA within the First 2 Years after Renal Transplantation
M. J. Everly¹, I. Purnajo¹, K. P. Briley², J. L. Beaumont¹, P. Bolin², S. A. Kendrick³, H. Jones³, K. McLawhorn³, A. Q. Maldonado⁴, D. Leeser², C. E. Haisch², L. M. Rebellato²
¹Terasaki Research Institute, Los Angeles, CA, ²East Carolina University, Greenville, NC, ³Eastern Nephrology Associates, Greenville, NC, ⁴Vidant Medical Center, Greenville, NC
*Purpose: Patients that receive an HLA-mismatched kidney transplant (KT) have an increased likelihood to develop de novo DSA (dnDSA). Ideally, immunosuppression is properly adjusted and…